Protagonist Therapeutics Inc (PTGX)

R&D to Revenue

346.16%

Fiscal year · Period ending:

PTGX logo

PTGX R&D to Revenue

Latest reported346.16%
PTGX FY R&D/Revenue (0.00% → 346.16%)
High-resolution chart · PNG

PTGX r&d to revenue history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.

Protagonist Therapeutics Inc R&D to Revenue — Annual fiscal periods
Period endingR&D to Revenue
346.1622%
31.795%
200.2683%
474.8316%
460.5987%
265.4185%
28,139.8268%
192.3913%
230.1799%
0%
0%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.